AOCMF 2nd ARONJ Conference—Anti-osteoclastic drugs, impact on maxillofacial and bone
Munich, Germany
17 Sep 2018
Download vCalendar file
Quick access

It is our pleasure to announce and invite you to attend the AOCMF's second conference on ARONJ ('Anti-osteoclastic drugs and their impact on maxillofacial and orthopedic bone biology, surgery, disease, and treatment'. The conference brings together leading principal investigators of AOCMF ARONJ projects who will share their results and encourage debate and discussion on the topic. This conference is open to all those interested and involved in this research field.

Learning objectives
Learn from the interim results of ARONJ AOCMF– supported projects
Benefit from diverse presentations and active discussions and participate in active project and treatment discussions
Find out more about the AOCMF
Eppo Wolvius  (Course Chair)
View all
View conflicts of interest
Level Principles
Region Europe and Southern Africa
Language(s) English
Scope International
Academic status Non peer reviewed
Format Symposium
Content Debates, Lectures
Target audience Clinical investigations, CMF musculoskeletal oncology, ENT surgery, General surgery, Neurosurgery, Oral and maxillofacial surgery, Other, Plastic surgery, Research, Residency
Closing date17 Sep 2018
Available places12
Cancellation policyNo refund for cancellations
Euro 150.00 EUR
Payment options and information
Payment is by credit card

Conference fee is:
150 Euro
105 Euro for students (indicated as resident discount - with proof of identity) and early registrations by Friday, 29 June 2018
Included services
Coffee breaks
Course materials
Complimentary hardcopy of the book "ARONJ Guide to Research"
Aperitif and finger food

Background to AOCMF ARONJ Clinical Priority Program (CPP)
Bisphosphonates (Alendronate, Zolendronate, Pamidronate and others) and additional anti-osteoclastic drugs such as RANKL inhibitors (Denosumab) are among the most prescribed drugs in the world today. 26 million prescriptions for Alendronate in the US alone are used for treatment of postmenopausal osteoporosis and 250,000 patients with metastatic bone cancer are treated with high dose intravenous bisphosphonates. These drugs have been noted to have profound influences on oral and orthopedic health including exacerbation of dental diseases, osteonecrosis of the jaw requiring ablation, spiral fractures of the femur, bone pain, and spinal and other foramenal stenosis, are some of the areas of impact associated with anti-osteoclastic drugs. These medications have also been associated with a marked decrease in femoral neck fractures, compression fractures of the spine and other osteoporotic fractures such as wrist and humerus.

AOCMF launched a CPP program sponsoring diverse research projects to investigate on the field of ARONJ and is excited to share further results after a very successful first AOCMF ARONJ Conference in 2016, in London.

Ms Mirjam Bucher (AOCMF R&D Senior Project Manager) ACVS Diplomate
Stettbachstr. 6
8600 Dübendorf

Congress Center Munich City Gasteig

Kleiner Konzertsaal, 1st Floor

Rosenheimer Str. 5

81667 Munich


Congress Center Munich City Gasteig